Evaxion Biotech A/S - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EVAX Nasdaq 8731 http://www.evaxion-biotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evaxion Biotech A/S - ADR

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients - Mar 23rd, 2023 11:55 am
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Mar 14th, 2023 8:30 pm
Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine - Feb 8th, 2023 3:47 pm
Evaxion and Pantherna announce promising preclinical mRNA vaccine data - Feb 8th, 2023 11:30 am
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy - Jan 19th, 2023 1:45 pm
Evaxion's stock soars after getting FDA approval for mid-stage cancer trial - Jan 3rd, 2023 1:14 pm
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01 - Jan 3rd, 2023 12:30 pm
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023 - Dec 15th, 2022 12:48 pm
Evaxion, ExpreS2ion Ink Research Pact For Cytomegalovirus Vaccine Candidate - Dec 6th, 2022 1:18 pm
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate - Dec 6th, 2022 7:00 am
Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy - Nov 17th, 2022 4:03 pm
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02 - Nov 17th, 2022 11:59 am
Evaxion Announces Third Quarter 2022 Financial Results and Business Update - Nov 14th, 2022 12:13 pm
Evaxion CEO comments on strategic focus - Nov 10th, 2022 9:10 am
10 Best Immunotherapy Stocks To Buy Now - Oct 11th, 2022 3:54 pm
Evaxion welcomes Per Norlén as new CEO. - Oct 5th, 2022 12:32 pm
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study - Sep 22nd, 2022 2:50 pm
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy - Sep 21st, 2022 9:45 am
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School - Sep 6th, 2022 11:02 am
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update - Aug 10th, 2022 11:00 am